LYFNUA Tablets 45 mg for refractory chronic cough (gefapixant)

What are LYFNUA Tablets 45 mg for refractory chronic cough (gefapixant)?

LYFNUA tablets offer a distinct approach to managing refractory chronic cough, potentially providing relief where other treatments may have limitations. These tablets function by targeting the underlying mechanism of chronic cough, potentially suppressing persistent coughing episodes. Central to their mechanism is the selective inhibition of nerve switches known as P2X3 receptors within the airways, crucial elements in the activation of sensory neurons responsible for triggering the cough reflex.

The active ingredient in LYFNUA tablets, gefapixant, stands out as an innovative solution in chronic cough treatment. As a first-in-class, non-narcotic, selective antagonist of the P2X3 receptor, gefapixant demonstrates notable efficacy in alleviating chronic cough symptoms. Multiple studies and clinical trials have highlighted the effectiveness of this active compound. For instance, in the article titled "Update on the clinical development of gefapixant, a P2X3 receptor antagonist for the treatment of refractory chronic cough," researchers affirm the capability of gefapixant to address both refractory chronic cough and unexplained chronic cough.

The benefits of LYFNUA tablets extend beyond symptom relief. By specifically targeting the P2X3 receptors, these tablets offer a tailored approach to chronic cough management, addressing the root cause of the condition. This targeted action may not only mitigate coughing episodes but also potentially improve overall quality of life for individuals grappling with refractory chronic cough.

In the realm of chronic cough treatment, LYFNUA tablets emerge as a promising option for those seeking effective relief. Their unique mechanism of action, powered by the potent antagonist gefapixant, sets them apart as a potential solution for refractory chronic cough. With their demonstrated efficacy and targeted approach, LYFNUA tablets represent a significant advancement in the management of chronic cough, offering potential hope and relief to patients where conventional treatments failed.

Active principles: gefapixant citrate

Amount: 100 tablets

Indications: refractory chronic cough

How to take: For adults, take one tablet (45 mg of gefapixant) twice daily. Patients with severe kidney disease not undergoing dialysis should take one tablet once daily. 

Contraindications and precautions: You may encounter taste impairments such as bitterness, metallic taste, saltiness, or difficulty sensing taste or enjoying food. If you have impaired kidney function, regular renal function tests may be necessary. Do not use for pregnant or breastfeeding women. Patients with kidney disease or dialytic treatment should consult with their doctor before use. Do not expose to sunlight or heat. If allergic symptoms occur, discontinue use.